Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection...

Full description

Bibliographic Details
Published in:MedComm
Main Authors: Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang
Format: Article
Language:English
Published: Wiley 2023-12-01
Subjects:
anti‐inflammatory
blood‐derived products
immunomodulatory
long COVID
passive immunotherapy
SARS‐CoV‐2 infection
Online Access:https://doi.org/10.1002/mco2.426

Internet

https://doi.org/10.1002/mco2.426

Similar Items